| abstract |
The invention relates to compounds of the general formula (I) wherein, R is hydrogen, -(CH2)n-phenyl, optionally substituted by halogen, lower alkyl, lower alkoxy, trifluoromethyl or -N(R')-C(O)-lower alkyl, -(CH2)n-pyridinyl, optionally substituted by lower alkyl, -(CH2)n-C3-6-cycloalkyl, optionally substituted by hydroxy, -(CH2)n-N(R')-C3-6-cycloalkyl, -(CH2)n-benzo[1,3]-dioxolyl, -(CR'2)n-thiophenyl, optionally substituted by lower alkyl, -(CR'2)n-thiazolyl, optionally substituted by lower alkyl, -(CH2)n-C(O)-thiophenyl, optionally substituted by halogen, -(CH2)n-furanyl, optionally substituted by lower alkyl, -(CH2)n-C(O)-(CH2)n-thiophenyl, -(CHR')n-benzofuran-2-yl, -(CH2)n-benzo[b]thiophenyl, optionally substituted by lower alkyl, -(CH2)n-N(R')-C(O)-phenyl, optionally substituted by halogen or lower alkoxy, -(CH2)n-C(O)-phenyl, optionally substituted by lower alkoxy, -(CH2)n-C(O)-2,3-dihydro-benzo [1,4]dioxin-6-yl, -(CH2)n-N(R')-C(O)-pyridinyl, -(CH2)n-tetrahydrofuranyl, -CH-bi-phenyl, -CH(phenyl)-pyridinyl, -(CH2)n-1-oxo-1,3-dihydro-isoindol-2-yl, -(CH2)n-1,3-dioxo-1,3-dihydro-isoindol-2-yl, -(CH2)n-CH(phenyl)-tetrahydropyranyl, -(CH2)n-1-oxo-1,2,3,4-tetrahydro-isoquinolin-3-yl or (CH2)n-S-[1,3,4]thiazol-2-yl, optionally substituted by amino; R' is hydrogen or lower alkyl, independently from each other in case R'2; and n is 0, 1, 2, 3 or 4; and pharmaceutically acceptable acid addition salts thereof. The compounds of formula I have a good affinity to the A2A receptor and they are therefore useful for the treatment of diseases, related to this receptor. |